Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin ≥ 100 mg/m2

M. G. Kris, R. A. Clark, L. B. Tyson, W. F. Hahne, K. M W Pisters, Richard J. Gralla

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Ondansetron, a serotonin antagonist antiemetic, controls emesis caused by cisplatin when given as multiple 0.15 mg/ kg dosages in a variety of administration schedules. This trial evaluated a single 0.45 mg/kg i.v. dose of ondansetron in 21 cancer patients receiving cisplatin at doses ≥ 100 mg/m2 as initial chemotherapy. Twenty-five percent of patients had no emetic episodes (95% confidence interval: 9-49%), and 45% had two or fewer emetic episodes (95% confidence interval: 23-69%). No significant adverse effects were seen. In prior trials at this institution in similarly treated patients, ondansetron given in three divided doses yielded a 42% no emesis rate. In this trial a single i.v. 0.45 mg/kg dose of ondansetron prevented emesis in 25% of patients receiving initial cisplatin ≥ 100 mg/m2. For this dose of cisplatin and ondansetron, the observed emesis complete control rate was lower than that previously seen using multiple dose schedules.

Original languageEnglish (US)
Pages (from-to)77-80
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number1
StatePublished - 1993
Externally publishedYes

Fingerprint

Ondansetron
Cisplatin
Vomiting
Emetics
Appointments and Schedules
Confidence Intervals
Serotonin Antagonists
Antiemetics
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin ≥ 100 mg/m2. / Kris, M. G.; Clark, R. A.; Tyson, L. B.; Hahne, W. F.; Pisters, K. M W; Gralla, Richard J.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 16, No. 1, 1993, p. 77-80.

Research output: Contribution to journalArticle

@article{04f8acc7d46d401bb882eb1321a3a856,
title = "Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin ≥ 100 mg/m2",
abstract = "Ondansetron, a serotonin antagonist antiemetic, controls emesis caused by cisplatin when given as multiple 0.15 mg/ kg dosages in a variety of administration schedules. This trial evaluated a single 0.45 mg/kg i.v. dose of ondansetron in 21 cancer patients receiving cisplatin at doses ≥ 100 mg/m2 as initial chemotherapy. Twenty-five percent of patients had no emetic episodes (95{\%} confidence interval: 9-49{\%}), and 45{\%} had two or fewer emetic episodes (95{\%} confidence interval: 23-69{\%}). No significant adverse effects were seen. In prior trials at this institution in similarly treated patients, ondansetron given in three divided doses yielded a 42{\%} no emesis rate. In this trial a single i.v. 0.45 mg/kg dose of ondansetron prevented emesis in 25{\%} of patients receiving initial cisplatin ≥ 100 mg/m2. For this dose of cisplatin and ondansetron, the observed emesis complete control rate was lower than that previously seen using multiple dose schedules.",
author = "Kris, {M. G.} and Clark, {R. A.} and Tyson, {L. B.} and Hahne, {W. F.} and Pisters, {K. M W} and Gralla, {Richard J.}",
year = "1993",
language = "English (US)",
volume = "16",
pages = "77--80",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin ≥ 100 mg/m2

AU - Kris, M. G.

AU - Clark, R. A.

AU - Tyson, L. B.

AU - Hahne, W. F.

AU - Pisters, K. M W

AU - Gralla, Richard J.

PY - 1993

Y1 - 1993

N2 - Ondansetron, a serotonin antagonist antiemetic, controls emesis caused by cisplatin when given as multiple 0.15 mg/ kg dosages in a variety of administration schedules. This trial evaluated a single 0.45 mg/kg i.v. dose of ondansetron in 21 cancer patients receiving cisplatin at doses ≥ 100 mg/m2 as initial chemotherapy. Twenty-five percent of patients had no emetic episodes (95% confidence interval: 9-49%), and 45% had two or fewer emetic episodes (95% confidence interval: 23-69%). No significant adverse effects were seen. In prior trials at this institution in similarly treated patients, ondansetron given in three divided doses yielded a 42% no emesis rate. In this trial a single i.v. 0.45 mg/kg dose of ondansetron prevented emesis in 25% of patients receiving initial cisplatin ≥ 100 mg/m2. For this dose of cisplatin and ondansetron, the observed emesis complete control rate was lower than that previously seen using multiple dose schedules.

AB - Ondansetron, a serotonin antagonist antiemetic, controls emesis caused by cisplatin when given as multiple 0.15 mg/ kg dosages in a variety of administration schedules. This trial evaluated a single 0.45 mg/kg i.v. dose of ondansetron in 21 cancer patients receiving cisplatin at doses ≥ 100 mg/m2 as initial chemotherapy. Twenty-five percent of patients had no emetic episodes (95% confidence interval: 9-49%), and 45% had two or fewer emetic episodes (95% confidence interval: 23-69%). No significant adverse effects were seen. In prior trials at this institution in similarly treated patients, ondansetron given in three divided doses yielded a 42% no emesis rate. In this trial a single i.v. 0.45 mg/kg dose of ondansetron prevented emesis in 25% of patients receiving initial cisplatin ≥ 100 mg/m2. For this dose of cisplatin and ondansetron, the observed emesis complete control rate was lower than that previously seen using multiple dose schedules.

UR - http://www.scopus.com/inward/record.url?scp=0027402802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027402802&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 77

EP - 80

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -